Related Experiment Video
Updated: Apr 18, 2026
11:20
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
4.5K
Incomplete vitreomacular traction release using intravitreal ocriplasmin
Eric K Chin1, David R P Almeida1, Elliott H Sohn1
1Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Case Reports in Ophthalmology
|January 22, 2015
Summary
Intravitreal ocriplasmin showed limited success in resolving vitreomacular traction and macular holes in seven patients, with a notable decrease in visual acuity post-treatment. Further analysis is needed for optimal outcomes.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacological Treatments
Background:
- Intravitreal ocriplasmin is a pharmacological agent used for vitreolysis.
- This study reports on the initial clinical experience with ocriplasmin in seven patients.
Observation:
- The study included seven patients with an average age of 78.4 years, treated between January and December 2013.
- Five patients were pseudophakic and two were phakic; baseline visual acuity averaged 20/60.
- One month post-injection, visual acuity averaged 20/70, representing a mean loss of two lines.
Findings:
- None of the seven patients achieved complete resolution of vitreomacular traction or macular hole at one month.
- Three patients required subsequent pars plana vitrectomy and membrane peeling surgery.
- One patient experienced increased intraocular pressure, managed with eye drops; no cases of uveitis, endophthalmitis, retinal tears, or detachment were observed.
Implications:
- Intravitreal ocriplasmin demonstrated incomplete resolution of vitreomacular traction and macular holes in this patient series.
- A reduction in visual acuity was observed one month after ocriplasmin treatment.
- Careful patient selection, considering the vitreoretinal interface and comorbidities, is crucial for optimizing outcomes with ocriplasmin.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:28Angle Closure Glaucoma: Treatment
1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
01:25Glaucoma: Overview
1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K